Many of the 61 million Americans with Medicare are wondering whether their out-of-pocket health costs will be higher in 2025 than in 2024 and, if so, by how much. The answer, like so much about Medicare,

Funding cuts and regulatory changes could radically reduce Medicaid, the largest program providing medical and health-related services to low-income people, as well as Medicare, federal health insurance for people 65 or older, and some under 65 with certain disabilities or conditions.

The Trump administration came into office earlier this week with a promise of cutting down on government spending and driving greater efficiency, but a new poll from KFF shows voters largely support continued spending on Medicare and Medicaid.

“Improving prescription drug affordability for Medicare enrollees is the core of the Inflation Reduction Act, and the next cycle of negotiations will continue to strengthen Medicare for generations to come," Chiquita Brooks-LaSure, administrator of the Centers for Medicare & Medicaid Services, said in the news release.

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental health conditions. However, they may cover the FDA-approved nasal spray, Spravato, which contains a derivative of ketamine called esketamine.

Donald Trump has rescinded an executive order from President Joe Biden that sought to lower the price of drugs.

Individuals in Hawaii have various options for Medicare. These include Original Medicare, Medicare Advantage, and Medicare Part D. Learn more here.

UnitedHealth Group Inc. promoted the head of its Medicare health plan business to lead the company’s broader insurance division, filling the job previously held by slain executive Brian Thompson. Tim Noel,

The General Enrollment Period provides an opportunity to make up for a past oversight — the failure to enroll in Part B.

Despite online claims, President Donald Trump’s executive orders did not include removing Medicare’s $35 monthly out-of-pocket price cap, which is set by law.

Legislation providing more scrutiny for pharmacy benefit managers (PBMs) that failed to make it through Congress in the waning days of 2024 seems to still be viable for passage this year, according to a House staff member.